MENU
SRPT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SRPT stock forecast, quote, news & analysis

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders... Show more

Industry: #Biotechnology
SRPT
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SRPT with price predictions
Sep 25, 2026

Aroon Indicator for SRPT shows an upward move is likely

SRPT's Aroon Indicator triggered a bullish signal on September 14, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 167 similar instances where the Aroon Indicator showed a similar pattern. In 145 of the 167 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in 227 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

SRPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for SRPT moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRPT as a result. In 65 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for SRPT turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 37 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

SRPT moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. SRPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.291) is normal, around the industry mean (26.565). P/E Ratio (45.486) is within average values for comparable stocks, (41.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.024). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1.125) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.37B. VRTX holds the highest valuation in this group at 133.37B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 5%. JAGX experienced the highest price growth at 184%, while CDT experienced the biggest fall at -54%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -55%. For the same stocks of the Industry, the average monthly volume growth was 27% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 61
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
SRPT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of treatments for life-threatening illnesses and viruses

Industry Biotechnology

Industry
Biotechnology
Address
215 First Street
Phone
+1 617 274-4000
Employees
835
Web
https://www.sarepta.com
Aroon Indicator for SRPT shows an upward move is likely